Radioembolization with yttrium-90 microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies - Part 3: Comprehensive literature review and future direction

Journal of Vascular and Interventional Radiology

Volumn 17, Issue 10, 2006, Pages 1571-1593

  Salem, Riad ^a,b   Thurston, Kenneth G ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; HOLMIUM; IRINOTECAN; MICROSPHERE; OXALIPLATIN; RHENIUM; SIR SPHERES; THERASPHERE; YTTRIUM 90;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTIFICIAL EMBOLISM; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRACHYTHERAPY; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DOSIMETER; DRUG SAFETY; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HEMOBILIA; HEPATIC ENCEPHALOPATHY; HUMAN; JAUNDICE; LEG EDEMA; LETHARGY; LEUKOPENIA; LIVER CANCER; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER METASTASIS; LIVER PAIN; LIVER TOXICITY; LIVER TRANSPLANTATION; MULTIPLE CANCER; NAUSEA; NEUTROPENIA; PANCREATITIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STOMACH ULCER; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 33750156243     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000236744.34720.73     Document Type: Article

References (149)

1. Flynn WJ. The treatment of pulmonary metastases with microspheres of yttrium 90. Minerva Med 1967; 58:4498-4500.
2. Greene WM. Embolization of dog prostates with yttrium-90 microspheres. J Urol 1963; 90:451-457.
3. Wollner I, Knutsen C, Smith P, et al. Effects of hepatic arterial yttrium 90 glass microspheres in dogs. Cancer 1988; 61:1336-1344.
4. Wollner IS, Knutsen CA, Ullrich KA, et al. Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs. Cancer Res 1987; 47:3285-3290.
5. Kulik L, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (Thera-Sphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RF ablation and bridge to transplantation. J Surg Oncol 2006 (in press).
6. Kulik LM, Mulcahy MF, Hunter RD, et al. Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl 2005; 11:1127-1131.
7. Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 2004; 240:299-305.
8. Lewandowski R, Salem R, Thurston K, et al. Radiation segmentectomy of unresectable of liver carcinoma using selective infusion of intraarterial yttrium-90 TheraSphere. Presented at the Radiological Society of North America; November 28-December 3, 2004; Chicago, IL.
9. Rhee TK, Omary RA, Gates V, et al. The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol 2005; 16:1085-1091.
10. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16:1627-1639.
11. Andrews JC, Walker SC, Ackermann RJ, et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994; 35:1637-1644.
12. Coldwell D, Nutting C, Kennedy AK. Treatment of hepatic metastases from breast cancer with yttrium-90 SIR-Spheres radioembolization. Presented at the Society of Interventional Radiology Annual Meeting; March 31 through April 5, 2005; New Orleans, LA.
13. Coldwell D, Nutting C, Kennedy AK. Use of yttrium-90 SirSpheres to treat metastatic unresectable neuroendorcine tumors to the liver. Presented at the World Congress of Gastrointestinal Cancer; June 27-30, 2005; Barcelona, Spain.
14. Coldwell D, Nutting C, Kennedy AS. Initial clinical results in the treatment of unresectable hepatic tumors with resin-based yttrium-90 radioembolization. Presented at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Annual Meeting; September 25-29, 2004; Barcelona, Spain.
15. Herba MJ, Illescas FF, Thirlwell MP, et al. Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology 1988; 169:311-314.
16. Kennedy A, Coldwell D, Nutting C, et al. Hepatic brachytherapy for GI neuroendocrine tumors with Y90 microspheres: long-term USA results. Presented at International Congress on Anti-cancer Treatment; February 1-4, 2005; Paris.
17. Rubin D, Nutting C, Jones B. Metastatic breast cancer in a 54-year-old woman: integrative treatment with yttrium-90 radioembolization. Integr Cancer Ther 2004; 3:262-267.
18. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88:78-85.
19. Van Hazel G, Price D, Bower G, et al. Selective internal radiation therapy (SIRT) plus systemic chemotherapy with FOLFOX4: a phase I dose escalation study. Presented at the American Society of Clinical Oncology Gastrointestinal Malignancies Symposium; February 27-29, 2005; Hollywood, FL.
20. Van Hazel G, Price D, Bower G, et al. Selective internal radiation therapy (SIRT) for liver metastases with concomitant systemic oxaliplatin, 5-fluorouracil and folinic acid: a phase I/II dose escalation study. Presented at the American Society of Clinical Oncology Gastrointestinal Malignancies Symposium; February 27-29, 2005; Hollywood, FL.
21. Ariel I. Intra-arterial injection of radioactive microspheres of ceramic in the treatment of malignant tumors. indications and clinical results. Minerva Med 1965; 56:2030-2037.
22. Ariel IM. Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (Y90 radiating microspheres). Ann Surg 1965; 162:267-278.
23. Ariel IM, Flynn W, Pack GT. Current possibilities of radioactive ceramic microspheres labeled with yttrium 90. Minerva Med 1967; 58:4496-4498.
24. Ariel IM, Padula G. Irradiation of the spleen by the intra-arterial administration of 90 yttrium microspheres in patients with malignant lymphoma: a preliminary report. Cancer 1973; 31:90-96.
25. Simon N, Siffert R, Baron MG, et al. Preoperative irradiation of osteogenic sarcoma with intra-arterially injected yttrium-90 microspheres: case report. Cancer 1968; 21:453-455.
26. Jaffe R, Simon N. Treatment of brain tumors with internally deposited yttrium 90. Neurology 1968; 18:309.
27. Pandey U, Bapat KN, Samuel G, et al. Evaluation of 90Y phosphate particles as a possible radiation synoviorthosis agent. Nucl Med Commun 2005; 26:459-463.
28. Sojan S, Bartholomeusz D. Cutaneous radiation necrosis as a complication of yttrium-90 synovectomy. Hell J Nucl Med 2005; 8:58-59.
29. Dunn AL, Manco-Johnson M, Busch MT, et al. Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy. J Thromb Haemost 2005; 3:1541-1542.
30. Chadzopoulos D, Badiavas K. Complications in 90Y radiation synovectomy. Hell J Nucl Med 2005; 8:134.
31. Sheppeard H, Aldin A, Ward DJ. Osmic acid versus yttrium-90 in rheumatoid synovitis of the knee. Scand J Rheumatol 1981; 10:234-236.
32. Chamberlain MN, Gray BN, Heggie JC, et al. Hepatic metastases - a physiological approach to treatment. Br J Surg 1983; 70:596-598.
33. Mantravadi RV, Spigos DG, Tan WS, et al. Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology 1982; 142:783-786.
34. Mantravadi RV, Spigos DG, Karesh SM, et al. Work in progress: intraarterial P-32 chromic phosphate for prevention of postoperative liver metastases in high-risk colorectal cancer patients. Radiology 1983; 148:555-559.
35. Hafeli UO, Casillas S, Dietz DW, et al. Hepatic tumor radioembolization in a rat model using radioactive rhenium (186Re/188Re) glass microspheres. Int J Radiat Oncol Biol Phys 1999; 44:189-199.
36. Nijsen F, Rook D, Brandt C, et al. Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study. Eur J Nucl Med 2001; 28:743-749.
37. Vuorela J, Kauppinen T, Sokka T. Distribution of radiation in synovectomy of the knee with 166Ho-FHMA using image fusion. Cancer Biother Radiopharm 2005; 20:333-337.
38. Yan L, Li L, Chen S. Radioembolization with 32P-labelled glass microspheres for advanced hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 1996; 34:526-529.
39. Yan L, Li Z, Li L, et al. The relationship between effects and radiation doses of intra-arterial phosphorus-32 glass microspheres embolization therapy for patients with advanced liver cancer. Chung-Hua Wai Ko Tsa Chih Chin J Surg 2000; 38:837-840.
40. Keng GH, Sundram FX, Yu SW, et al. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radioconjugates. Ann Acad Med Singapore 2002; 31:382-386.
41. Kumar A, Bal C, Srivastava DN, et al. Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-lipiodol. Eur J Gastroenterol Hepatol 2006; 18:219-223.
42. Kumar A, Srivastava DN, Bal C. Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil. J Vasc Interv Radiol 2006; 17:157-161.
43. Yoon CJ, Chung JW, Park JH, et al. Transcatheter arterial embolization with 188Rhenium-HDD-labeled iodized oil in rabbit VX2 liver tumor. J Vasc Interv Radiol 2004; 15:1121-1128.
44. Lin WY, Tsai SC, Hsieh JF, et al. Effects of 90Y-microspheres on liver tumors: comparison of intratumoral injection method and intra-arterial injection method. J Nucl Med 2000; 41:1892-1897.
45. Yan ZP, Lin G, Zhao HY, et al. Yttrium-90 glass microspheres injected via the portal vein: an experimental study. Acta Radiol 1993; 34:395-398.
46. Tian JH, Xu BX, Zhang JM, et al. Ultrasound-guided internal radiotherapy using yttrium-90-glass microspheres for liver malignancies. J Nucl Med 1996; 37:958-963.
47. Hafeli UO, Sweeney SM, Beresford BA, et al. Effective targeting of magnetic radioactive 90Y-microspheres to tumor cells by an externally applied magnetic field: preliminary in vitro and in vivo results. Nucl Med Biol 1995; 22:147-155.
48. Hafeli UO, Sweeney SM, Beresford BA, et al. Magnetically directed poly(lactic acid) 90Y-microspheres: novel agents for targeted intracavitary radiotherapy. J Biomed Mater Res 1994; 28:901-908.
49. Rudge S, Peterson C, Vessely C, et al. Adsorption and desorption of chemotherapeutic drugs from a magnetically targeted carrier (MTC). J Control Release 2001 74: 335-340.
50. Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol 2003 30(6 suppl 17):6-10.
51. Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2004; 59:1274-1287.
52. Toegel S, Mien LK, Wadsak W, et al. In vitro evaluation of no carrier added, carrier added and cross-complexed [90Y]-EDTMP provides evidence for a novel "foreign carrier theory." Nucl Med Biol 2006; 33:95-99.
53. Araki N, Nagata Y, Fujiwara K, et al. Evaluation of glass microspheres for intra-arterial radiotherapy in animal kidneys. Int J Radiat Oncol Biol Phys 2001; 49:459-463.
54. Becker CD, Rosler H, Biasiutti FD, et al. Congestive hypersplenism: treatment by means of radioembolization of the spleen with Y-90. Radiology 1995; 195:183-186.
55. Houle S, Yip TK, Shepherd FA, et al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology 1989; 172:857-860.
56. Shepherd FA, Rotstein LE, Houle S, et al. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992; 70:2250-2254.
57. Dong BW, Liang P, Jing XH. Combined treatment of hepatic carcinoma: percutaneous intratumoral injection of Y-90 glass treatment microspheres with sonographic guidance. Zhonghua Yi Xue Za Zhi 1994 74: 471-473,517.
58. Yan ZP, Lin G, Zhao HY, et al. An experimental study and clinical pilot trials on yttrium-90 glass microspheres through the hepatic artery for treatment of primary liver cancer. Cancer 1993; 72:3210-3215.
59. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000; 41:1673-1681.
60. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004 10(2 suppl 1):S107-110.
61. Salem R, Lewandowski R, Roberts C, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004; 15:335-345.
62. Lewandowski R, Alli A, Atassi B, et al. Retraction of portal vein thrombus following treatment with Y90 TheraSphere: a secondary sign of tumor response. Presented at the Society of Interventional Radiology Annual Meeting 2006; Toronto, ON, Canada.
63. Liu MD, Uaje MB, Al-Ghazi MS, et al. Use of yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. Am Surg 2004; 70:947-953.
64. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127(5 suppl 1):S194-S205.
65. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 2005; 16:195-203.
66. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005; 16:205-213.
67. Dawson LA. Hepatic arterial yttrium 90 microspheres: another treatment option for hepatocellular carcinoma. J Vasc Interv Radiol 2005; 16:161-164.
68. Atassi B, Lewandowski RJ, Kulik L, et al. Treatment of unresectable hepatocellular carcinoma using intra-arterial Y90 (TheraSphere®): long-term follow-up. Presented at the Society of Interventional Radiology Annual Meeting 2006; Toronto, ON, Canada.
69. Kim DY, Kwon DS, Salem R, et al. Successful embolization of hepatocelluar carcinoma with yttrium-90 glass microspheres prior to liver transplantation. J Gastrointest Surg 2006; 10:413-416.
70. Pompili M, Mirante VG, Rondinara G, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005; 11:1117-1126.
71. Wong LL, Tanaka K, Lau L, et al. Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transplant 2004; 18:227-234.
72. Anderson JH, Goldberg JA, Bessent RG, et al. Glass yttrium-90 microspheres for patients with colorectal liver metastases. Radiother Oncol 1992; 25:137-139.
73. Goin JE, Dancey JE, Hermann GA, et al. Treatment of unresectable metastatic colorectal carcinoma to the liver with intrahepatic Y-90 microspheres: a dose-ranging study. World J Nucl Med 2003; 2:216-225.
74. Wong CY, Salem R, Raman S, et al. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002; 29:815-820.
75. Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 2004; 45:1892-1897.
76. Lewandowski RJ, Thurston KG, Goin JE, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005; 16:1641-1651.
77. Ariel IM, Padula G. Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes. J Surg Oncol 1978; 10:327-336.
78. Atassi B, Lewandowski R, Mulachy M, et al. Treatment with yttrium-90 microspheres of unresectable metastatic colorectal cancer to the liver: safety, treatment response and survival. Presented at the American Society of Clinical Oncology Gastrointestinal Malignancies Symposium; 2006; San Francisco.
79. Blanchard RJ, Morrow IM, Sutherland JB. Treatment of liver tumors with yttrium-90 microspheres alone. Can Assoc Radiol J 1989; 40:206-210.
80. Herba MJ, Thirlwell MP. Radioembolization for hepatic metastases. Semin Oncol 2002; 29:152-159.
81. Lewandowski RJ, Atassi BA, Wong CO, et al. Use of yttrium-90 microspheres for the treatment of liver neoplasia: long-term follow-up. Presented at the Annual Meeting of the Cardiovascular and Interventional Society of Europe 2006; Rome.
82. Grady ED. Intrahepatic arterial 90-yttrium resin spheres to treat liver cancer. Int J Nucl Med Biol 1978; 5:253-254.
83. Grady ED. Internal radiation therapy of hepatic cancer. Dis Colon Rectum 1979; 22:371-375.
84. Grady ED, Auda SP, Cheek WV. Vasoconstrictors to improve localization of radioactive microspheres in the treatment of liver cancer. J Med Assoc Ga 1981; 70:791-795.
85. Grady ED, Nolan TR, Crumbley AJ, et al. Internal radiation therapy of liver cancer (90-Yttrium resin spheres intra-arterially) to supplement external radiation therapy, local and systemic chemotherapy. J Med Assoc Ga 1977; 66:625-629.
86. Grady ED, McLaren J, Auda SP, et al. Combination of internal radiation therapy and hyperthermia to treat liver cancer. South Med J 1983; 76:1101-1105.
87. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40:583-592.
88. Lau WY, Ho S, Leung WT, et al. What determines survival duration in hepatocellular carcinoma treated with intraarterial yttrium-90 microspheres? Hepatogastroenterology 2001; 48:338-340.
89. Szeto CC, Wong TY, Leung CB, et al. Selective internal radiation therapy by yttrium-90 microspheres for hepatocellular carcinoma after renal transplantation. Clin Transplant 2001; 15:284-288.
90. Gray BN, Burton MA, Kelleher DK, et al. Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate. J Surg Oncol 1989; 42:192-196.
91. Gray BN, Anderson JE, Burton MA, et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg 1992; 62:105-110.
92. Gray B, Van Hazel G, Hope M, et al. Randomized trial of SIR-Spheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12:1711-1720.
93. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg 2001; 5:294-302.
94. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology 2001; 48:333-337.
95. Geller DA, Carr BI, Amesur N, et al. Responses in Chemo-refractory metastases from colon cancer to a single dose of hepatic artery Y90 microspheres. Presented at the American Society of Clinical Oncology Annual Meeting; 2003; Chicago.
96. Goldstein D, Van Hazel G, Pavlakis N, et al. Selective internal radiation therapy (SIRT) plus systemic chemotherapy with irinotecan: a phase I dose escalation study. Presented at American Society of Clinical Oncology Annual Meeting; May 13-17, 2005; Orlando, FL.
97. Sharma RA, Van Hazel GA, Blanshard K, et al. Internal radiation treatment of liver metastases from colorectal cancer with concomitant systemic radiosensitising chemotherapy. Presented at the World Congress on Gastrointestinal Cancer 2006; Barcelona, Spain.
98. Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 2005; 16:937-945.
99. Lim LC, Gibbs P, Yip D, et al. A prospective evaluation of treatment with selective internal radiation therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMJ Cancer 2005 5: 132.
100. Kennedy AS, Coldwell D, Nutting C, et al. Resin (90)Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65:412-425.
101. Murthy R, Oh Y, Tam A, et al. Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Presented at the American Society of Clinical Oncology Annual Meeting; 2006; Atlanta.
102. Lim L, Gibbs P, Yip D, et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 2005; 35:222-227.
103. Kennedy AS, W D, McNeillie P, et al. Fractionation, dose selection, and response of hepatic metastases of neuroendocrine tumors after Y90 microsphere brachytherapy. Presented at the Annual Meeting of the American Brachytherapy Society; May 10-12, 2006; Philadelphia.
104. Popperl G, Helmberger T, Munzing W, et al. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. Cancer Biother Radiopharm 2005; 20:200-208.
105. Wong CY, Qing F, Savin M, et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 2005; 16:1101-1106.
106. Yu M, Lewandowski RJ, Wong COW, et al. Yttrium-90 (SIR-Spheres) treatment for metastatic cancer to the liver: midterm results. Presented at the Society of Interventional Radiology Annual Meeting 2006; Toronto, ON, Canada.
107. Jakobs TF, Hoffmann RT, Schmitz A, et al. Treatment of extensive metastatic liver disease with intrahepatic yttrium 90 microspheres: toxicity assessment. Presented at the Society of Interventional Radiology Annual Meeting 2006; Toronto, ON, Canada.
108. Jakobs TF, Hoffmann RT, Schmitz A, et al. Selective internal radiation therapy with yttrium-90 microspheres in metastatic liver disease: clinical results. Presented at the Society of Interventional Radiology Annual Meeting 2006; Toronto, ON, Canada.
109. Jakobs T, Hoffman RT, Yu M, et al. Yttrium-90 SIR-Spheres treatment for metastatic cancer to the liver: mid-term results. Presented at the World Conference on Interventional Oncology; 2006; Cernobbio, Italy.
110. Cianni R, Saltarelli A, Notarianni E, et al. Radioembolism (yttrium 90) of hepatic liver metastases: preliminary experience. Presented at the World Conference on Interventional Oncology; 2006; Cernobbio, Italy.
111. Wang S, Ho YY, Leung F, et al. Outcomes following selective internal with SIR-Spheres in non-resectable hepatic malignancy. Presented at the World Conference on Interventional Oncology; 2006; Cernobbio, Italy.
112. King J, Morris DL, Glenn D, et al. Pilot study of SIR-Spheres in liver metastases from neuroendocrine cancer (NETLM). Presented at the Third European Neuroendocrine Tumor Society (ENTS) Conference 2006. Prague, Czech Republic.
113. Coldwell D, Kennedy AK. Treatment of nodular cholangiocarcinoma with yttrium-90 microspheres. Presented at the World Congress on Gastrointestinal Cancer 2006; Barcelona, Spain.
114. Kennedy A, Coldwell D, Nutting C, et al. Liver brachytherapy for unresectable colorectal metastases: US results 2000-2004. Presented at the American Society of Clinical Oncology Gastrointestinal Malignancies Symposium; 2005. Hollywood, FL.
115. Wong CO, Savin M, Sherpa KM, et al. Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy refractory metastatic liver carcinoma. Cancer Biother Radiopharm 2006 (in press).
116. Garrean S, Espat NJ. Yttrium-90 internal radiation therapy for hepatic malignancy. Surg Oncol 2006 (in press).
117. Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol 2006; 23:64-72.
118. Georgiades CS, Salem R, Geschwind JF. Radioactive microspheres for the treatment of HCC. In: Golzarian J, ed. Vascular embolotherapy: a comprehensive approach. New York: Springer, 2005;141-148.
119. Salem R, Thurston KG, Geschwind JF. Yttrium-90 radioembolization for the treatment of liver metastases. In: Golzarian J, ed. Vascular embolotherapy: a comprehensive approach. New York: Springer, 2005;149-161.
120. Mulcahy MF, Benson AB III. Bevacizumab in the treatment of colorectal cancer. Exp Opin Biol Ther 2005; 5:997-1005.
121. Stathopoulos GP, Rigatos SK, Stathopoulos JG, et al. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin. Am J Clin Oncol 2005; 28:565-569.
122. Herscher LL, Cook JA, Pacelli R, et al. Principles of chemoradiation: theoretical and practical considerations. Oncology (Williston Park) 1999;13(10 suppl 5):11-22.
123. Florman S, Toure B, Kim L, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004; 8:208-212.
124. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 1998; 66:1307-1312.
125. Norton JA. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol 2005; 19:577-583.
126. Norton JA, Warren RS, Kelly MG, et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003;134: 1057-1063.
127. Dejong CH, Parks RW, Currie E, et al. Treatment of hepatic metastases of neuroendocrine malignancies: a 10-year experience. J R Coll Surg Edinb 2002; 47:495-499.
128. Grazi GL, Cescon M, Pierangeli F, et al. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 2000; 47:481-486.
129. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197:9-37.
130. Jaeck D, Oussoultzoglou E, Bachellier P, et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg 2001; 25:689-692.
131. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26:985-990.
132. Seifert JK, Cozzi PJ, Morris DL. Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 1998; 14:175-183.
133. Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 1995; 76:501-509.
134. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104:1590-1602.
135. Kress O, Wagner HJ, Wied M, et al. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors: a retrospective single-center analysis. Digestion 2003; 68: 94-101.
136. Delanoit T, Rubin J, Neczyporenko F, et al. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc 2005; 20:502-506.
137. di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77:402-408.
138. Angeletti S, Corleto VD, Schillaci O, et al. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours. Ital J Gastroenterol Hepatol 1999; 31:23-27.
139. Oberg K. Interferon-alpha versus somatostatin or the combination of both in gastro-enteropancreatic tumours. Digestion 1996;57(suppl 1):81-83.
140. Murthy R, Habbu AA, Richey SL, et al. Implications of patterns of metastases of colorectal cancer on liver-directed therapy in patients undergoing combination systemic treatment with irinotecan and cetuximab. Presented at the World Conference on Interventional Oncology; 2006; Cernobbio, Italy.
141. Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004; 60:1552-1563.
142. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236.
143. Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006; 29:522-529.
144. Voboril R. Blood supply of metastatic liver tumors: an experimental study. Int Surg 2005; 90 (2):71-77.
145. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36(5 suppl 1):S74-S83.
146. Kennedy AS, Dezern W, McNeillie P, et al. Dose selection of resin y90 microspheres for liver brachytherapy: a single center review. Presented at the Annual Meeting of the American Brachytherapy Society; May 10-12, 2006; Philadelphia.
147. Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005; 16:911-935.
148. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005;25(suppl 1):S41-S55.
149. Nutting C, Coldwell D, Kennedy AK. Coil embolization prevents gastrointestinal ulcers during yttrium-90 hepatic radioembolization. Presented at the Society of Interventional Radiology Annual Meeting 2004; Phoenix, AZ.